摘要
目的:探讨苯磺酸氨氯地平与阿托伐他汀联合治疗对原发性高血压病患者颈动脉内膜-中层厚度(IMT)的作用。方法:选择79例合并颈动脉硬化的原发性高血压病患者,随机分为对照组(39例)和试验组(40例)。对照组使用苯磺酸氨氯地平5mg,1次/d,2周后,血压未降至140/90mmHg以下者,增加剂量至10mg,试验组同时口服阿托伐他汀20mg,1次/晚,疗程为28周。比较两组治疗前、后的颈动脉IMT、血压、TG、TC、LDL-C、HDL-C、高敏C反应蛋白(hs-CRP)的变化。结果:服药28周后,两组IMT、血压均较治疗前明显降低(P<0.05);其中试验组IMT降低更明显(P<0.05)。试验组TG、TC、LDL-C、hsCRP明显下降,HDL-C明显增高,与治疗前及对照组治疗前、后比较,差异均有统计学意义(P<0.05)。结论:苯磺酸氨氯地平联合应用阿托伐他汀对颈动脉IMT消退作用更显著,能有效延缓原发性高血压病患者颈动脉硬化进展。
Objective： To explore the effect of amlodipine besylate and atoravastin on carotid artery intima-media thickness （ IMT ） in patients with essential hypertension. Methods： Seventy-nine patients with essential hyperten- sion complicated with carotid arteriosclerosis were randomly divided into control group （39 cases） and experimental group （40 cases）. Patients in control group were treated with amlodipine besylate 5mg/d, and the dosage was added to 10mg/d if the blood pressure was above 140/90mmHg after 2 weeks treatment. Patients in the experimental group were given atoravastin 20mg/d once every night for 28 weeks. The IMT of carotid artery, blood pressure, levels of TC, TG, LDL-C, HDL-C, hs-CRP were monitored before and after treatments. Results： The IMT and blood pressure decreased obviously in two groups 28 weeks after treatment （P〈0. 05）, and IMT decreased significantly in experimental group compared with that of control group （P〈0. 05）. Level of TG, TC, LDL-C and hsCRP decreased, and HDL-C increased significantly in experimental group than those in control group and before treatment （P〈0.05）. Conclusions： Combined application of Amlodipine besylate and atoravastin has significant effect on IMT of carotid artery in patients with essential hypertension, and it can delay the progression of essential hypertension.
出处
《内科急危重症杂志》
2009年第6期302-304,共3页
Journal of Critical Care In Internal Medicine
